BIONTECH SE-ADR (22UA.DE) Stock Price, Quote, News and Overview
FRA:22UA - Deutsche Boerse Ag - US09075V1026 - ADR - Currency: EUR
22UA.DE Quote, Performance and Key Statistics
BIONTECH SE-ADR
FRA:22UA (2/4/2025, 7:00:00 PM)
112.9
-4.9 (-4.16%)
The current stock price of 22UA.DE is 112.9 EUR. In the past month the price decreased by -8.14%. In the past year, price increased by 31.07%.
22UA.DE Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 18.69 | 323.32B | ||
| AMG.DE | AMGEN INC | 14.96 | 149.57B | ||
| 1AMGN.MI | AMGEN INC | 14.81 | 148.09B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 937.76 | 118.34B | ||
| GIS.DE | GILEAD SCIENCES INC | 21.97 | 117.44B | ||
| ARGX.BR | ARGENX SE | N/A | 37.66B | ||
| IDP.DE | BIOGEN INC | 8.75 | 20.15B | ||
| 0QF.DE | MODERNA INC | N/A | 13.30B | ||
| 1MRNA.MI | MODERNA INC | N/A | 13.08B | ||
| ALEMS.BR | EUROPEAN MEDICAL SOLUTIONS S | N/A | 9.95B | ||
| GLPG.AS | GALAPAGOS NV | 7 | 1.44B | ||
| NVV1.DE | NOVAVAX INC | N/A | 1.30B |
Related stock screener links
About 22UA.DE
Company Profile
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. The company is headquartered in Mainz, Rheinland-Pfalz and currently employs 6,133 full-time employees. The company went IPO on 2019-10-10. The firm focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The firm is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. The company also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Company Info
BIONTECH SE-ADR
An der Goldgrube 12
Mainz RHEINLAND-PFALZ DE
Employees: 6133
Company Website: https://www.biontech.com/
Investor Relations: https://investors.biontech.de/
Phone: 4949613190840
22UA.DE FAQ
What is the stock price of 22UA.DE?
The current stock price of 22UA.DE is 112.9 EUR.
What is the symbol for BIONTECH SE-ADR stock?
The exchange symbol of BIONTECH SE-ADR is 22UA and it is listed on the Deutsche Boerse Ag exchange.
On which exchange is 22UA.DE stock listed?
22UA.DE stock is listed on the Deutsche Boerse Ag exchange.
Is 22UA.DE a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for 22UA.DE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of 22UA.DE.
Does 22UA.DE stock pay dividends?
22UA.DE does not pay a dividend.
What is the Price/Earnings (PE) ratio of 22UA.DE?
22UA.DE does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.96).
22UA.DE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to 22UA.DE. When comparing the yearly performance of all stocks, 22UA.DE is one of the better performing stocks in the market, outperforming 88.79% of all stocks.
22UA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to 22UA.DE. 22UA.DE is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average.
22UA.DE Financial Highlights
Over the last trailing twelve months 22UA.DE reported a non-GAAP Earnings per Share(EPS) of -1.96. The EPS decreased by -117.52% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -2.08% | ||
| ROE | -2.44% | ||
| Debt/Equity | 0.01 |
22UA.DE Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 78% to 22UA.DE. The Buy consensus is the average rating of analysts ratings from 27 analysts.
For the next year, analysts expect an EPS growth of -183.58% and a revenue growth -38.3% for 22UA.DE